Recent price moves and what they might mean

RadNet (RDNT) has seen mixed recent trading, with the stock down about 2.6% in the latest session but up roughly 4.4% over the past week and 7.0% over the past month.

Over longer periods, returns have been uneven. The stock is down about 8.7% in the past 3 months and about 20.1% year to date, yet it has shown a modest 2.3% total return over the past year along with stronger multi year gains.

Pulling this together, RadNet’s recent 1 month share price rebound sits against weaker year to date share price returns and stronger multi year total shareholder returns. This suggests that momentum has been rebuilding after earlier weakness.

If you are comparing RadNet with other healthcare companies using AI, this is a good moment to see what stands out in the 40 healthcare AI stocks.

With RadNet trading at $56.71 and sitting at a discount to some estimated value and price targets, the key question is whether the current weakness signals mispricing or whether the stock already reflects its future growth potential.

Most Popular Narrative: 37% Undervalued

RadNet’s most followed narrative anchors fair value at about $89.75 per share, compared with the last close of $56.71. This frames a sizable valuation gap for investors to weigh.

Ongoing investments in AI-powered imaging solutions (e.g., DeepHealth, See-Mode, iCAD) are materially increasing center throughput, boosting capacity utilization, and driving more high-margin advanced procedures, directly enhancing both revenue growth and EBITDA margins as adoption scales through 2026.

Curious what underpins that jump from today’s loss to future profitability, plus a premium earnings multiple on top? The narrative leans on faster revenue growth, higher margins and a richer valuation profile than many healthcare peers, all rolled into one set of assumptions.

Result: Fair Value of $89.75 (UNDERVALUED)

However, this upside story could be knocked off course if reimbursement terms tighten or if heavy AI and acquisition spending keeps free cash flow under pressure.

Another way to look at value

The first view leans heavily on discounted cash flows and long term earnings assumptions. A simpler yardstick is the P/S ratio. RadNet trades at about 2.1x sales, which is higher than the US Healthcare industry at 1.3x and the company’s own fair ratio of 1x. This points to higher valuation risk if growth expectations slip.

For a closer look at how this sales based yardstick lines up with the rest of the numbers, have a read of the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

With mixed signals across price action, valuation and sentiment, the real question is how you weigh the trade off between those risks and rewards. Take a moment to look through the full picture for yourself with the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you only see one angle. Broaden your watchlist now so you do not miss stocks that better match your goals and risk comfort.

• Target potential value opportunities by scanning the 44 high quality undervalued stocks that combine quality fundamentals with pricing that may still be overlooked.
• Prioritize resilience by checking the 70 resilient stocks with low risk scores that score well on balance sheet strength and business risk factors.
• Spot earlier stage opportunities by reviewing the 24 elite penny stocks with strong financials that already show stronger financial profiles than many peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.